ADMA Biologics Faces Valuation Shift Amid Declining Profit and Operational Concerns

ADMA Biologics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting a shift in its valuation grade. The company's valuation has been categorized as very expensive, which is notable given its current financial metrics. The P/E ratio stands at 15, while the Price to Book Value is reported at 4.62. Additionally, the EV to EBIT and EV to EBITDA ratios are 11.43 and 10.97, respectively. Despite these metrics, the company has demonstrated a net sales growth rate of 64.60% annually, indicating potential for long-term growth. However, recent financial results for the quarter ending March 2026 showed a net profit of USD 94.71 million, which reflects a decline of 32.37%. The inventory turnover ratio has reached a low of 1 time, and the debtors turnover ratio is at 4.33 times, both of which may raise concerns about operational efficiency. Furthermore, ADMA Biologics has experienced a significant return of -52.30% over the past year, contrasting sharply with the S&P 500's return of 14.84%. With high institutional holdings at 100%, the company remains under close scrutiny by investors with substantial analytical resources. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.